Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients

British Journal of Clinical Pharmacology

Volumn 78, Issue 2, 2014, Pages 343-352

  Vezina, Heather E ^a,b   Brundage, Richard C ^a   Balfour Jr , Henry H ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

pharmacokinetics; pharmacometrics; prophylaxis; transplantation; valganciclovir

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY SIZE; CHILD; COMPARTMENT MODEL; CREATININE CLEARANCE; DEMOGRAPHY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GRAFT RECIPIENT; HERPES VIRUS INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION PREVENTION; KIDNEY FUNCTION; KIDNEY GRAFT; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIVER GRAFT; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEWBORN; PANCREAS TRANSPLANTATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TABLET FORMULATION; TREATMENT DURATION; ULTRAVIOLET DETECTION; ULTRAVIOLET SPECTROSCOPY; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BLOOD; HALF LIFE TIME; MIDDLE AGED; ORGAN TRANSPLANTATION; PRESCHOOL CHILD; VIRUS DISEASES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GANCICLOVIR; HALF-LIFE; HUMANS; INFANT; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; ORGAN TRANSPLANTATION; PROSPECTIVE STUDIES; VIRUS DISEASES; YOUNG ADULT;

EID: 84904858811     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12343     Document Type: Article

References (41)

1. Valcyte [Package Insert]. South San Francisco, CA: Genentech USA, Inc, 2010.
2. Cole NL, Balfour HH, Jr,. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diag Microbiol Infect Dis 1987; 6: 255-261.
3. Lin J-C, Smith MC, Pagano JS,. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J Virol 1984; 50: 50-55.
4. Akalin E, Sehgal V, Ames S, Hossain S, Daly L, Barbara M, Bromberg JS,. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3: 731-735.
5. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK,. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy 2004; 24: 1323-1330.
6. Keven K, Basu A, Tan HP, Thai N, Khan A, Marcos A, Starzl TE, Shapiro R,. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. Transplant Proc 2004; 36: 3107-3112.
7. Park JM, Lake KD, Arenas JD, Fontana RJ,. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 2006; 12: 112-116.
8. Manuel O, Venetz JP, Fellay J, Wasserfallen JB, Sturzenegger N, Fontana M, Matter M, Meylan PR, Pascual M,. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenolate-based regimen in kidney transplantation. Swiss Med Wkly 2007; 137: 669-676.
9. Weng FL, Patel AM, Wanchoo R, Brahmbhatt Y, Ribeiro K, Uknis ME, Mulgaonkar S, Mathis AS,. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants. Transplantation 2007; 83: 290-296.
10. Avidan YP, Paul M, Rahamimov R, Bishara J, Samra Z, Edna S, Mor E,. Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation. J Infect 2008; 57: 236-240.
11. Brady RL, Green K, Frei C, Maxwell P,. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis 2009; 11: 106-111.
12. Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JA, Farhan M, Peeters P,. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010; 90: 1427-1431.
13. Palmer SM, Limaye AP, Banks M, Gallup D, Chapman J, Lawrence EC, Dunitz J, Milstone A, Reynolds J, Yung GL, Chan KM, Aris R, Garrity E, Velantine V, McCall J, Chow SC, Davis RD, Avery R,. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152: 761-769.
14. Luan FL, Kommareddi M, Ojo AO,. Impact of cytomegalovirus disease in D+/R- kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis. Am J Transplant 2011; 11: 1936-1942.
15. Chamberlain CE, Penzak SR, Alfaro RM, Wesley R, Daniels CE, Hale D, Kirk AD, Mannon RB,. Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients. Am J Transplant 2008; 8: 1297-1302.
16. Manuel O, Pascual M, Perrottet N, Lamoth F, Venetz JP, Decosterd LA, Buclin T, Meylan PR,. Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study. Clin Transplant 2010; 24: 794-800.
17. Kiser TH, Fish DN, Zamora MR,. Evaluation of valganciclovir pharmacokinetics in lung transplant recipients. J Heart Lung Transplant 2012; 31: 159-166.
18. Perrottet N, Csajka C, Pascual M, Manuel O, Lamoth F, Meylan P, Aubert JD, Venetz JP, Soccal P, Decosterd LA, Biollaz J, Buclin T,. Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrob Agents Chemother 2009; 53: 3017-3023.
19. Weller DR, Balfour HH Jr, Vezina HE,. Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography. Biomed Chromatogr 2009; 23: 822-827.
20. Lindbom L, Pihlgren P, Jonsson EN,. Perl-speaks-NONMEM. Comput Methods Programs Biomed 2005; 79: 241-257.
21. Jonsson EN, Karlsson MO,. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
22. Anderson BJ, Holford NHG,. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-332.
23. Kleiber M,. Body size and metabolism. Hilgardia 1932; 6: 315-353.
24. Holford N,. A size standard for pharmacokinetics. Clin Pharm 1996; 30: 329-332.
25. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
26. Kukla A, El-Shahawi Y, Leister E, Kasiske B, Mauer M, Matas A, Ibrahim HN,. GFR-estimating models in kidney transplant recipients on a steroid-free regimen. Nephrol Dial Transplant 2010; 25: 1653-1661.
27. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A,. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976; 58: 259-563.
28. Schwartz GJ, Feld LG, Langford DJ,. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984; 104: 849-854.
29. Schwartz GJ, Gauthier B,. A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 1985; 106: 522-526.
30. Perl-speaks-NONMEM. 2013). Bootstrap user guide. Available at http://psn.sourceforge.net/pdfdocs/bootstrap-userguide.pdf (last accessed 9 December 2013).
31. Wiltshire H, Hirankarn S, Farrell C, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N,. Valganciclovir Solid Organ Transplant Study Group. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005; 44: 495-507.
32. Zhao W, Baudouin V, Zhang D, Deschenes G, Le Guellec C, Jacqz-Aigrain E,. Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients. Clin Pharmacokinet 2009; 48: 321-328.
33. Vaudry W, Ettenger R, Jara P, Varela-Fascinetto G, Bouw MR, Ives J, Walker R,. Valcyte WV16726 Study Group. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 2009; 9: 636-643.
34. Pescovitz MD, Ettenger RB, Strife CF, Sherbotie JR, Thomas SE, McDiarmid S, Bartosh S, Ives J, Bouw MR, Bucuvalas J,. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl Infect Dis 2010; 12: 195-203.
35. Vezina HE, Brundage RC, Nevins TE, Balfour HH, Jr,. The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein-Barr virus disease. Clin Pharmacol Adv Appl 2010; 2: 1-7.
36. McLeary SC, Morrish GA, Kirkpatrick CMJ, Green B,. The relationship between drug clearance and body size. Clin Pharmacokinet 2012; 51: 319-330.
37. Mahmood I,. Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther Drug Monit 2007; 29: 271-278.
38. Mahmood I,. Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metabol Drug Interact 2009; 24: 57-81.
39. Tang H, Hussain M, Leal E, Fluhler E, Mayersohn M,. Controversy in the allometric application of fixed- versus varying-exponent models: a statistical and mathematical perspective. J Pharm Sci 2011; 100: 402-410.
40. Wiltshire H, Paya CV, Pescovitz MD, Humar A, Dominguez E, Wahsburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Zuideveld KP,. Valganciclovir Solid Organ Transplant Study Group. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005; 79: 1477-1483.
41. Hocker B, Bohm S, Fickenscher H, Kusters U, Schnitzler P, Pohl M, John U, Kemper MJ, Fehrenbach H, Wigger M, Holder M, Schroder M, Feneberg R, Kopf-Shakib S, Tonshoff B,. Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation. Transpl Int 2012; 25: 723-731.